Stearoyl-CoA desaturase 5 (SCD5)

Stearoyl-CoA desaturase 5 (SCD5) is an integral membrane enzyme of the endoplasmic reticulum that catalyzes the introduction of a cis double bond into saturated fatty acyl-CoA substrates, converting saturated fatty acids into monounsaturated fatty acids[4]. SCD5 is one of two stearoyl-CoA desaturases in humans (the other being SCD1) and shows tissue-specific expression, being particularly abundant in the brain and adrenal gland[2][6]. SCD5 plays key roles in lipid metabolism, energy homeostasis, and the regulation of cell proliferation and differentiation, especially in neural and certain tumor cells[1][3]. Unlike SCD1, SCD5 appears unique to primates and has a narrow expression spectrum. Emerging evidence implicates SCD5 in the pathogenesis of several diseases. In cancer, lower SCD5 expression is linked to more aggressive breast cancer and melanoma, and SCD5 serves as a potential predictive biomarker for response to chemotherapy[2]. In neurological research, modulation of SCD5 is explored as a strategy to protect neurons in Parkinson’s disease by decreasing detrimental unsaturated fatty acids[3]. SCD5 also contributes to metabolic homeostasis, and genetic variations or alternative splicing of SCD5 may influence susceptibility to diabetes and obesity[1]. Its molecular and tissue specificity may render SCD5 a selective therapeutic target, but safety considerations related to disrupting basic lipid metabolism need to be carefully addressed.

Other names

ACOD4SCD2SCD4FLJ21032FADS4HSCD5acyl-CoA-desaturase 4stearoyl-CoA 9-desaturasestearoyl-CoA desaturase 2stearoyl-CoA desaturase 4DFNA79

Inhibition of SCD5 reduces the synthesis of monounsaturated fatty acids from saturated fatty acids, alters lipid profiles and impacts cellular processes such as proliferation, migration, and stress response[1][3]. RNAi therapeutics against SCD5 can block the production of SCD5 protein, potentially reducing alpha-synuclein toxicity in neurodegenerative diseases[3].